Changeflow GovPing Pharma & Drug Safety Mirati Therapeutics Files Patent for Substitute...
Routine Notice Added Final

Mirati Therapeutics Files Patent for Substituted Quinoxalines

Favicon for changeflow.com ChangeBridge: EPO Bulletin - Therapeutics (A61P)
Published March 18th, 2026
Detected March 25th, 2026
Email

Summary

The European Patent Office has published patent application EP4709714A1 filed by Mirati Therapeutics, Inc. for substituted quinoxalines. This publication relates to potential new therapeutic compounds.

What changed

The European Patent Office (EPO) has published patent application EP4709714A1, filed by Mirati Therapeutics, Inc., concerning substituted quinoxalines. The application, published on March 18, 2026, includes inventors from Mirati Therapeutics and lists various IPC classifications related to organic chemistry and therapeutic applications, specifically A61P 35/00 (antineoplastic agents).

This publication represents the granting of a patent application, not a new regulatory requirement for other entities. For Mirati Therapeutics, this signifies progress in their intellectual property portfolio for potential drug candidates. Compliance officers should note this as an indicator of R&D activity in the oncology space but no immediate compliance actions are required for other regulated entities.

Source document (simplified)

← EPO Patent Bulletin

SUBSTITUTED QUINOXALINES

Publication EP4709714A1 Kind: A1 Mar 18, 2026

Applicants

Mirati Therapeutics, Inc.

Inventors

MARX, Matthew, Arnold, SMITH, Christopher, Ronald, KETCHAM, John, Michael, HARWOOD, Stephen, BURNS, Aaron, Craig, LAWSON, John, David, CADDELL-HAATVEIT, Kersti

IPC Classifications

C07D 241/44 20060101AFI20241122BHEP C07D 401/04 20060101ALI20241122BHEP C07D 401/12 20060101ALI20241122BHEP C07D 401/14 20060101ALI20241122BHEP C07D 403/04 20060101ALI20241122BHEP C07D 417/12 20060101ALI20241122BHEP C07D 491/18 20060101ALI20241122BHEP C07D 491/20 20060101ALI20241122BHEP C07D 498/20 20060101ALI20241122BHEP A61P 35/00 20060101ALI20241122BHEP A61K 31/498 20060101ALI20241122BHEP

Designated States

AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR

View original document →

Named provisions

Substituted Quinoxalines

Classification

Agency
EPO
Published
March 18th, 2026
Instrument
Notice
Legal weight
Non-binding
Stage
Final
Change scope
Minor
Document ID
EP4709714A1

Who this affects

Applies to
Drug manufacturers Pharmaceutical companies
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Drug Development Intellectual Property Filing
Geographic scope
European Union EU

Taxonomy

Primary area
Pharmaceuticals
Operational domain
Legal
Compliance frameworks
FDA 21 CFR Part 11 GxP
Topics
Intellectual Property Drug Development

Get Pharma & Drug Safety alerts

Weekly digest. AI-summarized, no noise.

Free. Unsubscribe anytime.

Get alerts for this source

We'll email you when ChangeBridge: EPO Bulletin - Therapeutics (A61P) publishes new changes.

Free. Unsubscribe anytime.